Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?

The major constituent of green tea, (-)-epigallocatechin-3-O-gallate (EGCG), has been shown to have cancer-preventive and therapeutic activities. Numerous molecular targets for EGCG have been proposed, but the mechanisms of its anticancer activities are not clearly understood. In this issue of the J...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 123; no. 2; pp. 556 - 558
Main Authors Yang, Chung S, Wang, Hong
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.02.2013
Subjects
Animals
Antioxidants
Apoptosis
Apoptosis - physiology
Bioavailability
Biomedical research
Cancer
Cancer therapies
Care and treatment
Cells
Cyclic GMP - metabolism
Dihydrofolate reductase
Enzyme inhibitors
Enzymes
Female
Genetic aspects
Green tea
Health aspects
Humans
Investigations
Lymphoma
Male
Metastasis
Neoplasms - metabolism
Neoplasms - pathology
Physiological aspects
Polyphenols
Prostate
Proteins
Receptors, Laminin - metabolism
Tea
United States
Online AccessGet full text

Cover

More Information
Summary:The major constituent of green tea, (-)-epigallocatechin-3-O-gallate (EGCG), has been shown to have cancer-preventive and therapeutic activities. Numerous molecular targets for EGCG have been proposed, but the mechanisms of its anticancer activities are not clearly understood. In this issue of the JCI, Kumazoe et al. report that EGCG activates 67-kDa laminin receptor (67LR), elevates cGMP levels, and induces cancer cell apoptosis. Furthermore, a phosphodiesterase 5 inhibitor, vardenafil, synergizes with EGCG to induce cancer cell death. This is a provocative observation with important implications for cancer therapy. It also raises several issues for further investigation, such as the mechanism by which EGCG specifically activates 67LR.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ObjectType-Feature-1
ISSN:0021-9738
1558-8238
DOI:10.1172/JCI67589